Article category

  • HOME
  • ARTICLE CATEGORY
  • Article category
Original Article
1682
Impact of nationwide hepatocellular carcinoma surveillance on the prognosis in patients with chronic liver disease
Won Sohn, Danbee Kang, Minwoong Kang, Eliseo Guallar, Juhee Cho, Yong-Han Paik
Clin Mol Hepatol. 2022;28(4):851-863.   Published online June 3, 2022
View: 4318   Download: 190  Web of Science: 19  Crossref: 16
1712
Forecasted 2040 global prevalence of nonalcoholic fatty liver disease using hierarchical bayesian approach
Michael H. Le, Yee Hui Yeo, Biyao Zou, Scott Barnet, Linda Henry, Ramsey Cheung, Mindie H. Nguyen
Clin Mol Hepatol. 2022;28(4):841-850.   Published online September 19, 2022
View: 5469   Download: 217  Web of Science: 60  Crossref: 65
1688
Auranofin attenuates hepatic steatosis and fibrosis in nonalcoholic fatty liver disease via NRF2 and NF- κB signaling pathways
Seung Min Lee, Dong Hee Koh, Dae Won Jun, Yoon Jin Roh, Hyeon Tae Kang, Ju Hee Oh, Hyun Sung Kim
Clin Mol Hepatol. 2022;28(4):827-840.   Published online June 22, 2022
View: 6310   Download: 346  Web of Science: 15  Crossref: 16
1685
The usefulness of metabolic score for insulin resistance for the prediction of incident non-alcoholic fatty liver disease in Korean adults
Jun-Hyuk Lee, Kyongmin Park, Hye Sun Lee, Hoon-Ki Park, Jee Hye Han, Sang Bong Ahn
Clin Mol Hepatol. 2022;28(4):814-826.   Published online June 9, 2022
View: 4491   Download: 182  Web of Science: 12  Crossref: 14
Editorial
Surveillance for hepatocellular carcinoma: It is time to move forward
Bo Hyun Kim, Yuri Cho, Joong-Won Park
Clin Mol Hepatol. 2022;28(4):810-813.   Published online September 6, 2022
View: 2728   Download: 88  Web of Science: 5  Crossref: 5
1701
Repurposing drugs to target nonalcoholic steatohepatitis: Auranofin, a gold-organic molecule complex for the treatment of a specifc complex trait
Carlos J. Pirola, Silvia Sookoian
Clin Mol Hepatol. 2022;28(4):806-809.   Published online August 19, 2022
View: 2273   Download: 61
Review
1678
Nonalcoholic fatty liver disease versus metabolic-associated fatty liver disease: Prevalence, outcomes and implications of a change in name
Cheng Han Ng, Daniel Q. Huang, Mindie H. Nguyen
Clin Mol Hepatol. 2022;28(4):790-801.   Published online May 11, 2022
View: 6679   Download: 482  Web of Science: 40  Crossref: 41
Impact of diabetes, obesity, and dyslipidemia on the risk of hepatocellular carcinoma in patients with chronic liver diseases
Hwang Sik Shin, Baek Gyu Jun, Sang-Wook Yi
Clin Mol Hepatol. 2022;28(4):773-789.   Published online August 8, 2022
View: 4650   Download: 245  Web of Science: 13  Crossref: 14
1668
Old and new classes of glucose-lowering agents as treatments for non-alcoholic fatty liver disease: A narrative review
Lei Miao, Jing Xu, Giovanni Targher, Christopher D Byrne, Ming-Hua Zheng
Clin Mol Hepatol. 2022;28(4):725-738.   Published online March 14, 2022
View: 4555   Download: 244  Web of Science: 7  Crossref: 10
1666
The emerging roles of extracellular vesicles as intercellular messengers in liver physiology and pathology
Youngseok Lee, Jong-Hoon Kim
Clin Mol Hepatol. 2022;28(4):706-724.   Published online March 2, 2022
View: 12282   Download: 266  Web of Science: 9  Crossref: 10
Guideline
1713
2022 KLCA-NCC Korea practice guidelines for the management of hepatocellular carcinoma
Clin Mol Hepatol. 2022;28(4):583-705.   Published online October 1, 2022
View: 10014   Download: 667  Web of Science: 94  Crossref: 103
Snapshot
1693
Microbiome and metabolomics in alcoholic liver disease
Raja Ganesan, Ki Tae Suk
Clin Mol Hepatol. 2022;28(3):580-582.   Published online July 1, 2022
View: 4253   Download: 149  Web of Science: 3  Crossref: 4
Letter to the Editor
1672
Clinical significance of the discrepancy between radiological findings and biochemical responses in atezolizumab plus bevacizumab for hepatocellular carcinoma
Hideki Iwamoto, Shigeo Shimose, Takashi Niizeki, Hironori Koga, Takuji Torimura
Clin Mol Hepatol. 2022;28(3):575-579.   Published online April 21, 2022
View: 3153   Download: 201  Web of Science: 6  Crossref: 6
Original Article
1681
The effect of diabetes and prediabetes on the prevalence, complications and mortality in nonalcoholic fatty liver disease
Cheng Han Ng, Kai En Chan, Yip Han Chin, Rebecca Wenling Zeng, Pei Chen Tsai, Wen Hui Lim, Darren Jun Hao Tan, Chin Meng Khoo, Lay Hoon Goh, Zheng Jye Ling, Anand Kulkarni, Lung-Yi Loey Mak, Daniel Q Huang, Mark Chan, Nicholas WS Chew, Mohammad Shadab Siddiqui, Arun J. Sanyal, Mark Muthiah
Clin Mol Hepatol. 2022;28(3):565-574.   Published online May 19, 2022
View: 6379   Download: 190  Web of Science: 41  Crossref: 43
1679
Effect of moderate-to-severe hepatic steatosis on neutralising antibody response among BNT162b2 and CoronaVac recipients
Ka Shing Cheung, Lok Ka Lam, Rex Wan Hin Hui, Xianhua Mao, Ruiqi R Zhang, Kwok Hung Chan, Ivan FN Hung, Wai Kay Seto, Man-Fung Yuen
Clin Mol Hepatol. 2022;28(3):553-564.   Published online May 11, 2022
View: 3272   Download: 87  Web of Science: 9  Crossref: 9
1677
Reappraisal of sepsis-3 and CLIF-SOFA as predictors of mortality in patients with cirrhosis and infection presenting to the emergency department: A multicenter study
Ji Hyun Kim, Baek Gyu Jun, Minjong Lee, Hye Ah Lee, Tae Suk Kim, Jeong Won Heo, Da Hye Moon, Seong Hee Kang, Ki Tae Suk, Moon Young Kim, Young Don Kim, Gab Jin Cheon, Soon Koo Baik, Dong Joon Kim, Dae Hee Choi
Clin Mol Hepatol. 2022;28(3):540-552.   Published online May 6, 2022
View: 4248   Download: 114  Web of Science: 2  Crossref: 2
1676
Gut-derived lipopolysaccharide promotes alcoholic hepatosteatosis and subsequent hepatocellular carcinoma by stimulating neutrophil extracellular traps through toll-like receptor 4
Yang Liu, Xin Zhang, Shuo Chen, Jiazhong Wang, Shuo Yu, Yiming Li, Meng Xu, Harouna Aboubacar, Junhui Li, Tao Shan, Jixin Wang, Gang Cao
Clin Mol Hepatol. 2022;28(3):522-539.   Published online May 4, 2022
View: 4765   Download: 177  Web of Science: 14  Crossref: 14
1669
Association of non-alcoholic fatty liver disease with incident dementia later in life among elder adults
Seogsong Jeong, Yun Hwan Oh, Seulggie Choi, Jooyoung Chang, Sung Min Kim, Joung Sik Son, Gyeongsil Lee, Joseph C Ahn, Dong Hyeon Lee, Bo Kyung Koo, Won Kim, Sang Min Park
Clin Mol Hepatol. 2022;28(3):510-521.   Published online March 17, 2022
View: 5780   Download: 275  Web of Science: 25  Crossref: 24
1675
Discovery of dipeptidyl peptidase-4 inhibitor specific biomarker in non-alcoholic fatty liver disease mouse models using modified basket trial
Ju Hee Oh, Dae Won Jun, Hye Young Kim, Seung Min Lee, Eileen L. Yoon, Jungwook Hwang, Jung Hwan Park, Hanbi Lee, Wankyu Kim, Hyunsung Kim
Clin Mol Hepatol. 2022;28(3):497-509.   Published online April 28, 2022
View: 5403   Download: 164  Web of Science: 6  Crossref: 4
1667
Non-alcoholic fatty liver disease increases risk of carotid atherosclerosis and ischemic stroke: An updated meta-analysis with 135,602 individuals
Ansel Shao Pin Tang, Kai En Chan, Jingxuan Quek, Jieling Xiao, Phoebe Tay, Margaret Teng, Keng Siang Lee, Snow Yunni Lin, May Zin Myint, Benjamin Tan, Vijay K Sharma, Darren Jun Hao Tan, Wen Hui Lim, Apichat Kaewdech, Daniel Huang, Nicholas WS Chew, Mohammad Shadab Siddiqui, Arun J Sanyal, Mark Muthiah, Cheng Han Ng
Clin Mol Hepatol. 2022;28(3):483-496.   Published online March 2, 2022
View: 6901   Download: 259  Web of Science: 37  Crossref: 46
Editorial
Association of nonalcoholic fatty liver disease with incident dementia later in life among elderly adults
Byoung Seok Ye
Clin Mol Hepatol. 2022;28(3):481-482.   Published online May 16, 2022
View: 2635   Download: 69  Web of Science: 1  Crossref: 2
A crystal ball to forecast treatment responsiveness in nonalcoholic fatty liver disease
Seonghwan Hwang, Won Kim
Clin Mol Hepatol. 2022;28(3):478-480.   Published online June 16, 2022
View: 2920   Download: 89
1687
Does nonalcoholic fatty liver disease predispose patients to carotid arteriosclerosis and ischemic stroke?
Qian Jin, Rui-Xu Yang, Jian-Gao Fan
Clin Mol Hepatol. 2022;28(3):473-477.   Published online June 22, 2022
View: 3297   Download: 92  Web of Science: 2  Crossref: 2
Review
1692
Therapeutic mechanisms and beneficial effects of non-antidiabetic drugs in chronic liver diseases
Han Ah Lee, Young Chang, Pil Soo Sung, Eileen L. Yoon, Hye Won Lee, Jeong-Ju Yoo, Young-Sun Lee, Jihyun An, Do Seon Song, Young Youn Cho, Seung Up Kim, Yoon Jun Kim
Clin Mol Hepatol. 2022;28(3):425-472.   Published online July 1, 2022
View: 6926   Download: 356  Web of Science: 12  Crossref: 13
1664
RNA interference as a novel treatment strategy for chronic hepatitis B infection
Rex Wan-Hin Hui, Lung-Yi Mak, Wai-Kay Seto, Man-Fung Yuen
Clin Mol Hepatol. 2022;28(3):408-424.   Published online February 17, 2022
View: 7775   Download: 610  Web of Science: 28  Crossref: 33
1658
Intrahepatic cholangiocarcinoma: Tumour heterogeneity and its clinical relevance
Mina Komuta
Clin Mol Hepatol. 2022;28(3):396-407.   Published online January 14, 2022
View: 5549   Download: 337  Web of Science: 14  Crossref: 16
Statin and aspirin for chemoprevention of hepatocellular carcinoma: Time to use or wait further?
Myung Ji Goh, Dong Hyun Sinn
Clin Mol Hepatol. 2022;28(3):380-395.   Published online January 13, 2022
View: 4589   Download: 168  Web of Science: 10  Crossref: 9

Clinical and
Molecular
Hepatology

Print ISSN: 2287-2728
Online ISSN: 2287-285X

Editorial Office
The Korean Association for the Study of the Liver
Room A1210, 53 Mapo-daero(MapoTrapalace, Dowha-dong), Mapo-gu, Seoul, 04158, Korea
TEL: +82-2-703-0051   FAX: +82-2-703-0071    E-mail: kasl@kams.or.kr
Copyright © The Korean Association for the Study of the Liver.         
COUNTER
TODAY : 1075
TOTAL : 1782699
Close layer